Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izuforant in Cholinergic Urticaria
NCT04853992Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JW1601 in Cholinergic Urticaria (CU), sponsored by JW Pharmaceutical Corporation. Started May 2021; status: completed.
02
Drugs
JW1601
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on NCT04853992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853992.